Volgende studies zijn wetenschappelijk en behandelen de effecten van cannabinoïden op kankercellen:
(1). D.I. Abrams, H.P. Vizoso, S.B. Shade, C. Jay, M.E. Kelly en N.L. Benowitz (2007). Vaporization as a Smokeless Cannabis Delivery System: A Pilot Study. Clin Pharmacol Ther 82: 572-578.
(2). Manuel Guzman (2003). Cannabinoids: potential anticancer agents. Nature 3: 745-755.
(3). Robert Melamede (2005). Harm reduction-the cannabis paradox. Harm Reduct J 2: 17.
(4). M. Salazar, A. Carracedo, Í.J. Salanueva, S. Hernández-Tiedra, M. Lorente, A. Egia, P. Vázquez, C. Blázquez, S. Torres, S. García, J. Nowak, G.M. Fimia, M. Piacentini, F. Cecconi, P.P. Pandolfi, L. González-Feria, J.L. Iovanna, M. Guzmán, P. Boya en G. Velasco (2009). Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 119: 1359-1372.
(5). J.P. Marcu, R.T. Christian, D. Lau, A.J. Zielinski, M.P. Horowitz, J. Lee, A. Pakdel, J. Allison, C. Limbad, D.H. Moore, G.L. Yount, P.-Y. Desprez en S.D. McAllister (2010). Cannabidiol enhances the inhibitory effects of ?9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9: 180-189.
(6) A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira en F.S. Guimarães (2006). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39: 421-429.
(7). R.J. McKallip, C. Lombard, M. Fisher, B.R. Martin, S. Ryu, S. Grant, P.S. Nagarkatti en M. Nagarkatti (2002). Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100: 627-634.
(8). M.L. Casanova, C. Blazquez, J. Martinez-Palacio, C. Villanueva, M.J. Fernandez-Acenero, J.W. Huffman, J.L. Jorcano en M. Guzman (2003). Inhibition of skin tumor growth and angiogenisis in vivo by activation of cannabinoid receptors J Clin Invest 111: 43-50.
(9). G. Portella, C. Laezza, P. Laccetti, L. De Petrocellis, V. Di Marzo en M. Bifulco (2003. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17: 1771-1773.
(10). A. Ligresti, T. Bisogno, I. Matias, L. De Petrocellis, M.G. Cascio, V. Cosenza, G. D'argenio, G. Scaglione, M. Bifulco, I. Sorrentini en V. Di Marzo (2003). Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125: 677-687.
(11). A. Ligresti, A.S. Moriello, K. Starowicz, I. Matias, S. Pisanti, L. De Petrocellis, C. Laezza, G. Portella, M. Bifulco en V. Di Marzo (2006). Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. JPET 318: 1375-1387.
(12). M. Mimeault, N. Pommery, N. Wattez, C. Bailly en J.P. Hénichart (2003). Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56: 1-12.
(13). P. Nagarkatti, R. Pandey, S.A. Rieder, V.L. Hegde en M. Nagarkatti (2009). Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 1: 1333-1349.
(14). Robert Ramer en Burkhard Hinz (2007). Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1. JNCI J Natl Cancer Inst 100: 59-69.
(15). T.C. Wu, D.P. Tashkin, B. Djahed en J.E. Rose (1988). Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med 318: 347-351.
(16). John D. Minna (2003). Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. J Clin Invest 111: 31-33.
(17). B. Gardner,L.X. Zhu, S. Sharma, D.P. Tashkin en S.M. Dubinett (2003). Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J 17: 2157-2159.
(18). S. Sidney, C.P. Jr. Quesenberry, G.D. Friedman, I.S. Tekawa (1997). Marijuana use and cancer incidence (California, United States). Cancer Causes Control 8: 722-728.
(19). M. Hashibe, K. Straif, D.P. Tashkin, H. Morgenstern, S. Greenland, en Z.F. Zhang (2005). Epidemiologic review of marijuana use and cancer risk. Alcohol 35: 265-275.
(20). M. Hashibe, H. Morgenstern, Y. Cui, D.P. Tashkin, Z.-F. Zhang, W. Cozen, T.M. Mack en S. Greenland (2006). Marijuana Use and the Risk of Lung and Upper Aerodigestive Tract Cancers: Results of a Population-Based Case-Control Study. Cancer Epidemiol Biomarkers Prev 15: 1829.
(21). S. Aldington, M. Harwood, B. Cox, M. Weatherall, L. Beckert, A. Hansell, A. Pritchard, G. Robinson en R. Beasley (2008). On behalf of the Cannabis and Respiratory Disease Research Group Cannabis use and risk of lung cancer: a case–control study. Eur Respir J 31: 280-286.
(22). R.A. Sewell, A.J. Cohn en M.C. Chawarski (2008). Doubts about the role of cannabis in causing lung cancer. Eur Respir J 32: 815-816.
(23). R. Singh, J. Sandhu, B. Kaur, T. Juren, W.P. Steward, D. Segerba en P.B. Farmer (2009). Evaluation of the DNA Damaging Potential of Cannabis Cigarette Smoke by the Determination of Acetaldehyde Derived N2-Ethyl-2'-deoxyguanosine Adducts. Chem Res Toxicol 22: 1181-1188.
(24). C. Blazquez, M.L. Casanova, A. Planas, T.G. Del Pulgar, C. Villanueva, M.J. Fernandez-Acenero, J. Aragones, J.W. Huffman, J.L. Jorcano en M. Guzman (2003). Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17: 529-531.
(25). M. Guzmán, M.J. Duarte, C. Blázquez, J. Ravina, M.C. Rosa, I. Galve-Roperh, C. Sánchez, G. Velasco en L. González-Feria (2006). A pilot clinical study of ?9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal Of Cancer 95: 197-203
edit : Blijkbaar is Monsanto bezig met het patenteren van bepaalde cannabis kruisingen, omdat deze dan zogezegd 'speciaal' en patenteerbaar zouden zijn. Gezien de macht van de farma, zal cannabis pas legaal worden wanneer het herverpakt in een pilletje aangeboden wordt. Mensen zullen dit onder het mom van wetenschap en onderzoek dan wel gaan aanvaarden.